After Adverse Reaction In United Kingdom, Serum Institute Halts Indian Trials Of Oxford-AstraZeneca Covid-19 Vaccine

Pune-based Serum Institute of India (SII), world's largest vaccine maker by volume, on Thursday (10 September) halted the trials of Oxford-AstraZeneca's Covid-19 vaccine in India until the British-Swedish drugmaker AstraZeneca restarts them.

The development comes a day after AstraZeneca had paused a late-stage trial of its Covid-19 vaccine following a suspected adverse reaction in a study participant in UK.

Following the incident, AstraZeneca had put on hold the trials of the vaccine and would only restart them after a review by a data safety monitoring board.

Earlier on Wednesday (9 September), the Serum Institute had said that Indian trials of the vaccine will continue as the company had not faced any issues in the trials. It had also said that the AstraZeneca had paused the trials for review and it could restart soon.